newsfilter
← Earnings
Earnings Releases·

Rocket Pharmaceuticals — Third Quarter 2026 Earnings Summary

  • Q3 2026 net loss narrowed to $49.2 million ($0.43/share) from $50.3 million ($0.45/share) in the prior year period; R&D expenses decreased to $31.2 million while G&A rose to $19.8 million.
  • Cash and investments increased to $279.4 million as of September 30, 2026, with management projecting operations to be funded into Q3 2028, potentially extending to 2029 via the Hercules credit facility.
  • Secured a $150 million credit facility with Hercules Capital on October 6, 2026, with an initial $35 million draw and additional tranches contingent on options and clinical milestones.
  • RP-A501 (Danon disease) achieved FDA alignment for its pivotal Phase 2 trial, targeting dosing completion by mid-2027; KRESLADI™ reached commercial readiness on October 1, 2026, with two treatment centers activated.
  • Nine-month 2026 net income was $26.4 million ($0.23/share), a significant turnaround from a $180.6 million loss in the prior year, driven primarily by a $178.2 million gain from the sale of PRV.
Company
ROCKET PHARMACEUTICALS INC
Sector
Healthcare
Industry
Biotechnology